The ClpP protease is found in all kingdoms of life, from bacteria to humans. In general, this protease forms a homo-oligomeric complex composed of 14 identical subunits, which associates with its cognate Atpase in a symmetrical manner. Here we show that, in contrast to this general architecture, the clp protease from Mycobacterium smegmatis (Msm) forms an asymmetric hetero-oligomeric complex ClpP1P2, which only associates with its cognate ATPase through the ClpP2 ring. Our structural and functional characterisation of this complex demonstrates that asymmetric docking of the ATPase component is controlled by both the composition of the ClpP1 hydrophobic pocket (Hp) and the presence of a unique C-terminal extension in ClpP1 that guards this Hp. Our structural analysis of Msm ClpP1 also revealed openings in the side-walls of the inactive tetradecamer, which may represent sites for product egress.
active Mtb Clp protease complex was asymmetric in nature, composed of a single heptameric ring of each protein and that the activator docked into the substrate binding pocket as a substrate agonist 24 . Finally, the asymmetric nature of the ClpP1P2 complex from Mtb was also shown to extend to its peptidase specificity and its interaction with its cognate ATPase components 25, 26 .
In this study we have examined the activation and assembly of the ClpP1P2 complex from Mycobacterium smegmatis (Msm). Similar to the ClpP1P2 complex from Mtb, we show that Msm ClpP1P2 forms an asymmetric complex. The asymmetric nature of this complex is not limited to the composition of the tetradecamer but also extends to the peptidase activity of the complex (including propeptide processing), and interaction with its cognate ATPase components. In this case, our biochemical and structural analysis revealed that asymmetric docking of the ATPase components (to Msm ClpP1P2) is controlled by two elements within Msm ClpP1. Firstly, by a C-terminal extension in Msm ClpP1 that obstructs access of the ATPase component to the Hp and secondly by residues that line the Hp. Together with our analysis of the Ec ClpP Hp, we have identified Y88 (I104 in Ec ClpP) as a key feature of ATPase docking specificity. In addition, our structure of Msm ClpP1 reveals small openings in the side wall of the ClpP1 tetradecamer, which may represent exit portals for the egress of cleaved polypeptides.
Results and Discussion
Processing of the Msm ClpP2 propeptide by the active site residues of Msm ClpP1 does not require an activator. Given that correct processing of ClpP propeptides is crucial for ClpP peptidase activity 27 , we examined the processing of both Msm ClpP components. Initially, in order to determine if both Msm ClpP subunits were processed, we co-expressed untagged ClpP1 together with His 10 tagged ClpP2 (ClpP2 H10 ) in E. coli and co-purified the active Msm ClpP1P2 complex. Although recovery of the active hetero-oligomeric complex was poor, only one component ( Msm ClpP2) was processed, and this processing only occurred when the other component (ClpP1) was present ( Fig. S1 ). To determine the location of the processing site we cloned Msm clpP1 and clpP2, expressed them in E. coli and purified the individual components to analyse propeptide cleavage in vitro. Consistent with the co-expression experiment, the processing of Msm ClpP2, required Msm ClpP1 (Fig. 1) . Interestingly, although these data are similar to the processing of the Mtb ClpP1P2 complex, in which both ClpP subunits are processed by a hetero-oligomeric complex 21, 28 processing of Msm ClpP2 occurred in the absence of any additional components (Fig. 1b) . In contrast to the processing of Msm ClpP2, processing of both Mtb ClpP subunits required either the artificial activator z-LL 21 (also see Fig. S2 ) or a cognate ATPase component 25 . To determine the site of processing, we performed Edman degradation of ClpP1 and processed ClpP2 (pClpP2) from the in vitro processing assay. Similar to Ec ClpP and Mtb ClpP2 (processed between Ala 12 and Arg 13 ), Msm ClpP2 was processed between residues Ala 16 and Arg 17 . However, in contrast to Mtb ClpP1, which was processed between Met 7 and Arg 8 21, 28 , no processing of Msm ClpP1 was observed. Next we asked, how does processing of Msm ClpP2 occur? Initially, to address this question, we generated active site mutants of Msm ClpP1 (ClpP1 in ) and Msm ClpP2 (ClpP2 in ), in which the active site Ser (Ser95 and Ser114, respectively) were replaced with Ala. Similar to the processing of Mtb ClpP2 28 , mutation of the active site Ser in Msm ClpP2 ( Msm ClpP2 in ) did not affect processing ( Fig. 1c ), while in contrast processing was completely abolished by mutation of the active site Ser in Msm ClpP1 (Fig. 1d ). Collectively, these data demonstrate that processing of Msm ClpP2 is not autocatalytic, rather it appears to occur in trans via the catalytic triad of Msm ClpP1. An alternative interpretation of these data is that the catalytic triad of Msm ClpP2 was not active. Therefore, to ensure that the . The in vitro processing of (b) wild type Msm ClpP2 into processed (p) Msm ClpP2 (pClpP2) or (c) inactive Msm ClpP2 (ClpP2 in ) into processed ClpP2 in (pClpP2 in ), was monitored in the absence of activator (z-LL). (d) Processing of Msm ClpP2 (in the absence of z-LL), failed to occur in the presence of the proteolytically inactive ClpP1 mutant (ClpP1 in ).
catalytic triad of wild type Msm ClpP2 was active, we examined the turnover of different model substrates (from short peptides to a folded protein), by various mixed (wild type and mutant) ClpP1P2 complexes ( Fig. S3 ). These data demonstrated that although the catalytic triad of ClpP2 was active it was not essential for the turnover of all substrates. For example, although the active site of ClpP2 was dispensable for the turnover of short peptide substrates ( Fig. S3a ,b, compare lanes 2 and 6) it was necessary for efficient Ec ClpX-mediated turnover of the model protein substrate, GFP-Ec SsrA (Fig. S3c , blue triangles). Interestingly, although mutation of ClpP1 completely inhibited the turnover of peptide substrates it had little effect on the rate of native protein turnover ( Fig. S3c , red squares). In contrast mutation of ClpP2 slowed the turnover of GFP-Ec SsrA (Fig. S3c , blue triangles). Collectively, these data suggest that both ClpP1 and ClpP2 exhibit unique substrate specificities and that entry of a protein substrate (via Ec ClpX) into the proteolytic chamber may be unidirectional.
Next, in order to gain a better understanding of how in trans processing might occur we examined propeptide processing of various heterologous component combinations ( Fig. 2 ). Initially we monitored the ability of Mtb ClpP1 to facilitate the processing of Msm ClpP2 in the absence or presence of z-LL ( Fig. 2a ). Interestingly, consistent with the processing of Msm ClpP2 by Msm ClpP1 (Fig. 1b ), z-LL was not required for the Mtb ClpP1-mediated processing of Msm ClpP2, despite an absolute requirement of z-LL for all Mtb ClpP1 activities ( Fig. S2 ). Furthermore, the processing of Mtb ClpP1 was not required for processing of Msm ClpP2 to occur. Hence these data suggest that the initial processing event (of ClpP2) may occur by a mechanism that is distinct from the downstream processing of ClpP1. We then monitored the ability of Msm ClpP1 to facilitate the processing of Mtb ClpP2 (Fig. 2b) . Surprisingly, despite the fact that z-LL was not required for the Msm ClpP1-mediated processing of Msm ClpP2, it (z-LL) was essential for the processing of Mtb ClpP2. This suggests that z-LL is required to trigger a conformational change in Mtb ClpP2 that mediates its processing by Msm ClpP1.
Msm ClpP2 is processed via a transient complex. Although propeptide processing of homo-oligomeric
ClpP complexes such as Ec ClpP and Homo sapiens ClpP ( Hs ClpP) has long been described as autocatalytic 7 , the mechanism by which this step occurs is poorly defined and currently it remains unclear if processing occurs before (or as a result of) assembly of the tetradecamer, or indeed if processing occurs via the cis or trans ring 7, 27, 29 . Therefore, we examined the composition of the active "processing" complex. For homo-oligomeric ClpP complexes, it is plausible that processing is mediated by the cis ring and the processing site is determined via a molecular "ruler" mechanism. For hetero-oligomeric complexes such as ClpP1P2 24 , the distance between the processing site (within the propeptide) and the active site within the trans ring (~47 Å) is estimated to be much greater than the distance between the propeptide and the active site in the cis ring (~25 Å). Hence, to determine if processing of ClpP2 is mediated by formation of the ClpP1P2 complex, we generated single point mutations in both Msm ClpP proteins to disrupt the ring-ring interface. This mutation was based on a critical Arg residue that stabilises the ring-ring interface of Staphylococcus aureus ClpP ( Sa ClpP) 30 . Specifically, we replaced the Arg-finger residue in Msm ClpP1 and Msm ClpP2 (Arg168 and Arg189, respectively) with Ala. Initially, to ensure the overall structure of each mutant protein was not compromised, we compared the oligomeric state of each protein in the absence of z-LL using analytical ultracentrifugation (AUC). Importantly, both wild type and mutant Msm ClpP1 and Msm ClpP2 each formed heptamers ( Fig. S4 , red circles). Next, to monitor the effect of these mutations on Msm ClpP1P2 complex formation we performed a series of pull-down experiments, in which wild type or mutant Msm ClpP1 H10 was immobilised to Ni-NTA-agarose beads. Importantly, mutation of a single component was sufficient to significantly reduce its interaction with the other component ( Fig. 3 ), while mutation of both components almost completely abolished the interaction of the two components (Fig. 3b, lane 6) . These data demonstrate that, similar to Sa ClpP, the Arg finger plays a crucial role in stabilising the Msm ClpP1P2 complex. Consistent with this loss of the ClpP1P2 tetradecamer, the turnover of a model peptide ( Fig. 3c ) or protein ( Fig. 3d ) substrate, by each of the different mutant protein complexes, was completely abolished. Surprisingly, and in contrast to the peptidase activity of each mutant protein complex, all three complexes retained the ability to process ClpP2, with only a modest change to the rate of processing ( Fig. 3e ). One explanation for these data is that the substrate (i.e. the propeptide) is, in this case, tethered to the peptidase and hence any residual interaction between the two rings may be sufficient to facilitate rapid cleavage of the propeptide. An alternative explanation for these data is that processing of ClpP2 is not mediated by the classic ClpP1P2 tetradecamer, but rather by an interaction that does not require inter-ring contacts mediated by the Arg fingers. Consistent with this idea, propeptide processing of Msm ClpP2 (by Msm ClpP1) is independent of z-LL activity ( Fig. 1) , while in contrast the activator is essential for all other proteolytic activities of the Msm ClpP1P2 complex.
Mutation of the hydrophobic pocket modulates the peptidase activity of the Msm ClpP1pP2 com plexes. Next, in order to study the interaction of the Msm ClpP1P2 complex with its cognate ATPase components (ClpX and ClpC1), we generated specific point mutations within the hydrophobic pockets of Msm ClpP1 and Msm ClpP2. Initially, we targeted two residues in the Hp (the first was a highly conserved tyrosine residue found in all ClpP sequences, Y60 in ClpP1 and Y79 in ClpP2, the second hydrophobic residue was less conserved across ClpP sequences, Y110 in ClpP1 and L129 in ClpP2). Each of the hydrophobic residues (described above) was replaced with alanine, to generate a series of single point mutants (P1 Y60A , P1 Y110A , P2 Y79A or P2 L129A ) and one double mutant of Msm ClpP2 in which both hydrophobic residues (Y79 and L129) were replaced with alanine, here referred to as P2 dbl . To ensure that mutation of the Hp of Msm ClpP1 and Msm ClpP2, did not alter the overall structure of each protein, we examined the oligomeric state of each Hp mutant using AUC and compared them to the wild type proteins ( Fig. S4 ). Importantly, with the exception of P1 Y60A , the oligomeric state (as determined by AUC) of each mutant was largely unaffected (Fig. S4) . A similar trend for ClpP1 mutants was also observed using Native-PAGE ( Fig. S4 ), although in this case, again with the exception of P1 Y60A the gel appeared to stabilize the 14-mer. Stabilisation of the 14-mer by Native-PAGE has also been observed for human ClpP 29 . Surprisingly, neither the 7-mer nor the 14-mer complexes of ClpP2 were observed in Native-PAGE.
Next, we compared the peptidase activity of the wild type Msm ClpP1P2 complex with the various Msm ClpP1 and Msm ClpP2 mutant proteins ( Fig. S5 ). Interestingly, despite the changes to the oligomeric state of P1 Y60A only a small change in the rate of AAF-amc turnover (by P1 Y60A P2) was observed ( Fig. S5a ), while in contrast, the rate of LY-amc turnover by P1 Y60A P2 was unexpectedly increased by ~4-fold ( Fig. S5b ). Collectively these data appear to suggest that the replacement of aromatic residues (e.g. Y60A) within the Hp of ClpP1 may affect the conformation of the substrate binding pocket (S1) directly, which in the presence of the peptide agonist z-LL, could modulate substrate affinity, specificity and/or cleavage. Consistently, ClpP1 is directly responsible for the turnover of both peptide substrates, as replacement of the active site Ser of Msm ClpP1 with Ala (P1 in ) abolished the turnover of both substrates (Fig. S3 ). In contrast to P1 Y60A the relative peptidase activity of P1 Y110A (by the P1 Y110A P2 complex) was essentially unchanged for both substrates (Fig. S5a,b) . Importantly, given that P1 Y110A did not exhibit any substrate-dependent defects in peptidase activity, we limited our subsequent analysis to the ClpP1 Y110A P2 complex. Next, we examined the effect of the different Hp mutations in Msm ClpP2. Surprisingly, the peptidase rate for both substrates was significantly reduced (by up to 80%) for both single point mutants (Y79A and L129A) of Msm ClpP2 (P2 Y79A and P2 L129A ) ( Fig. S5c,d) . Intriguingly, the rate of peptide degradation by the double mutant (P2 dbl ) was unchanged for both substrates (Fig. S5c,d , compare columns 1 and 4). Currently it remains unclear why the peptidase activity of the two single mutants in complex with wild type ClpP1 is reduced. However, given that the double mutant exhibited a similar peptidase activity to the wild type complex, all further analysis was limited to the ClpP1P2 dbl complex. Msm ClpP1P2 forms asymmetric complexes with its cognate ATPase. To determine the mode of ATPase docking to the Msm ClpP1P2 complex, we examined the degradation of several ATPase-dependent substrates in the presence of wild type or mutant complexes of Msm ClpP1P2. Initially, we examined the ATPase-dependent turnover of GFP-Ec SsrA by Hp mutants of Msm ClpP1 (in the presence of wild type ClpP2) using the non-cognate ATPase, Ec ΔNClpX. Consistent with recent findings 31 , Ec ΔNClpX was able to mediate the turnover of GFP-Ec SsrA by Msm ClpP1P2, either in the absence or presence of the peptide activator, z-LL. Significantly, despite differences in peptidase activity of the various ClpP1 Hp mutants (Fig. S5) the Ec ΔNClpX -mediated turnover of GFP-Ec SsrA by each mutant protein complex was equivalent to the wild type complex (Fig. S6 ). Next, we examined the Ec ΔNClpX-mediated turnover of the same substrate by ClpP1P2 complexes bearing Hp mutations in ClpP2 (Fig. S6 ). Importantly, mutation of either or both Hp residues on ClpP2 abolished the ATPase-mediated turnover of GFP-Ec SsrA (Fig. S6 ). Collectively, these data suggest that the ATPase component docks exclusively to ClpP2. To confirm the asymmetric nature of the Msm ClpP1P2 complex we monitored the turnover of two additional model substrate that are mediated by Mycobacterial ATPase components (i.e. GFP-Mtb SsrA for ClpX and fluorescently-labelled model unfolded protein, FITC-casein for ClpC1). In this case, given that the "ClpP docking loop" of each ATPase component (ClpX and ClpC1) is conserved across Msm and Mtb (Fig. S7) , the turnover of each substrate by the various Hp mutant complexes was examined in the presence of either Mtb ClpX or Mtb ClpC1, respectively. Consistent with the asymmetric binding observed for Ec ΔNClpX, the Mtb ClpX-dependent turnover of GFP-Mtb SsrA was unaffected by mutation of the Hp in Msm ClpP1 ( Fig. 4 lane 5) . In contrast, the equivalent Hp mutation in Msm ClpP2 completely abolished substrate turnover (Fig. 4, lane 6) . Similarly, the Mtb ClpC1-dependent turnover of FITC-casein was unaffected by mutation of the Hp in Msm ClpP1 (Fig. 4, lane 8) , while the equivalent Hp mutation in Msm ClpP2 effectively abolished the turnover of FITC-casein (Fig. 4, lane 9 ). Collectively these data indicate that, mutation of the Hp in Msm ClpP2 is sufficient to completely abolish the turnover of substrates by all ATPases tested. Indeed, both the cognate ATPases ( Mtb ClpX and Mtb ClpC1) and the heterologous ATPase ( Ec ClpX) bind specifically to Msm ClpP2 and not to Msm ClpP1 forming single-headed, asymmetric complexes (ClpP1P2X and ClpP1P2C1). These data are consistent with the findings by Weber-Ban and colleagues who showed that the Mtb ClpP1P2 complex only binds to its partner unfoldase components through ClpP2 25 . Next, to better understand the molecular basis of this asymmetric specificity we compared the Hp residues of several ClpP homologs. From this analysis we noticed that in contrast to most ClpP sequences, Msm ClpP1 contained an additional aromatic residue (Y88) within the Hp and speculated that this aromatic residue inhibited ATPase docking (Fig. S8) . To test this hypothesis, we first replaced the equivalent residue in Ec ClpP (I104) with tyrosine to generate Ec ClpP I104Y and tested the ability of this mutant protein to interact with its cognate ATPase components (ClpA and ClpX). Consistent with the idea that Y88 is a crucial inhibitory element within the Hp, Ec ClpP I104Y prevented the ClpA-mediated degradation of GFP-Ec SsrA (Fig. 5a ). However, the same mutation had www.nature.com/scientificreports www.nature.com/scientificreports/ no effect on the ClpX-mediated turnover of SsrA-tagged GFP (Fig. 5b) . Interestingly, although the introduction of tyrosine at residue 104 (in Ec ClpP) was sufficient to inhibit ClpA docking, Ec ClpP (bearing Ile at residue 104) was unable to functionally interact with either Mtb ClpC1 (Fig. 5c , open red triangles) or Mtb ClpX (Fig. 5d , open red triangles). In contrast to ClpA docking, replacement of Ile104 with Tyr in Ec ClpP ( Ec ClpP I104Y ), did not affect Ec ClpX-docking. However, this mutation was sufficient to recover wild type-like activity with Mtb ClpX. Collectively these data indicate that tyrosine (at residue 104/88) although inhibitory to ClpA and ClpC1 docking is permissive to ClpX docking. This in turn suggests that residue 104/88 may act as a "sensor" of ATPase docking and not simply a key inhibitory element within Msm ClpP1, that obstructs ATPase docking.
Structural basis for docking asymmetry of Msm ClpP1P2. To better understand the molecular features that define ATPase docking we crystallised Msm ClpP1 (Fig. 6 ). The structure of Msm ClpP1 was determined to 2.0 Å resolution and refined to an R free value of 21.5% (Table 1 ). Similar to other ClpP structures, Msm ClpP1 was composed of two heptameric rings stacked back-to-back (the asymmetric unit consisted of one heptamer, the www.nature.com/scientificreports www.nature.com/scientificreports/ biological tetradecamer is formed from crystallographically related heptamers). The tetradecamer forms a compact barrel-shaped oligomer with approximate dimensions 86 × 102 Å (Fig. 6a ). The overall fold of the Msm ClpP1 protomer is similar to most ClpP structures; structural superposition of Msm ClpP1 with Mtb ClpP1 (2CBY) 32 , Mtb ClpP1P2 (4U0G) 24 and Ec ClpP (3MT6) 17 resulted in overall r.m.s.d. values of 0.8 Å (1183 Cα aligned), 2.3 Å (1024 Cα aligned) and 2.6 Å (1071 Cα aligned), respectively. However, there are a number of notable differences between these structures. Firstly, the structure of Msm ClpP1, similar to Mtb ClpP1 32 , is in an inactive conformation, as His120 is dislocated from the catalytic triad (i.e. the distance between Ser95 and His120 is 5.8 Å (Fig. 6b , right panel) (6.55 Å for the equivalent residues Mtb ClpP1). In contrast, in the ClpP1 component of the Mtb ClpP1P2 complex (4U0G) and in Ec ClpP, these residues are only 2.9 Å apart (Fig. 6b, left panel) . Another key difference between these structures relates to the formation of the tetradecamer, via the handle domains. In Ec ClpP and Mtb ClpP1P2 complex, the two heptameric rings associate via the formation of an antiparallel β-sheet in the handle domains, whereby each β-sheet is composed of strands from opposing monomers across the ring-ring interface. Compared to these active structures, both Msm ClpP1 and Mtb ClpP1, have shorter handle domains, which lack a structured β-strand region. As a result, association of the heptameric rings in Msm ClpP1 (and Mtb ClpP1) is mediated largely by a trans association of a short section of the α-helix in the handle domain creating several openings in the side-walls of the ClpP1 tetradecamer ( Figs. 6c and S9) . Although handle flexibility has been observed in a selection of inactive ClpP structures, the size and precise location of pores resulting from this flexibility has been difficult to assess due to the large number of unmodeled residues in these structures. Significantly, the breaches in the side wall of Msm ClpP1 are located adjacent to the catalytic residues of the protease and as such provide a direct path between the active site of the protease and the external solution. Hence as has been proposed by Kay and Houry 33 , these openings could represent an exit portal for the egress of peptides. Therefore, we postulate that this structure of Msm ClpP1 represents a post "substrate-cleavage" snapshot of the protease. Following peptide cleavage, this protease acquires an inactive conformation where the catalytic His residue adopts a distorted configuration, which initiates a conformational change in the adjacent handle domain whereby the β-strand that typically forms an antiparallel β-sheet with the equivalent β-strand in the opposite monomer, becomes disordered. As a result of this disorder in the β-strand, several interactions which stabilise the tetradecamer are lost. This results in a shorter interface between opposing subunits in the tetradecamer and opening of "large pores" along the surface of the protein which could allow release of the cleaved peptides. Smaller solvent exposed channels have also been observed in the side walls of the Mtb ClpP1P2 complex (Fig. S9 ), however these openings were only located between ClpP1 subunits, above the equatorial interface, ~15 Å from the catalytic triad 24 .
Another distinctive feature of Msm ClpP1, which is absent in many ClpP homologues including Mtb ClpP1 24,32 , is a short C-terminal extension (CTE) ~12 residues long, which docks into its own Hp (Fig. 6d) . Interestingly, the CTE interacts with residues within the Hp of ClpP in a similar manner to ADEP 16, 17, 24 . Specifically, the CTE interacts with three tyrosine residues (Y60, Y88 and Y110) within the Hp (Fig. 6d ). Hence, we speculated that, similar to ADEPs, the CTE of Msm ClpP1 may restrict ATPase docking. To test this idea, we deleted the CTE of Msm ClpP1 and monitored the ability of various wild type and mutant Msm ClpP1P2 complexes to interact with different ATPase components (Figs. 6e and S10). First, we examined the Ec ClpX-mediated turnover of GFP-Ec SsrA by Msm ClpP1 ΔCTE in the presence of wild type Msm ClpP2. Importantly, this complex retained wild type-like activity against each ATPase/substrate combination tested, demonstrating that removal of the CTE does not alter ClpP1P2 activity (Fig. 6e, open symbols) . Next, in order to switch ATPase-docking specificity (from Msm ClpP2 to Msm ClpP1), we repeated the above experiments in the presence of Msm ClpP2 dbl (which is unable to dock to any of the ATPase components tested). Remarkably, deletion of the CTE was sufficient to facilitate the Ec ClpX-mediated turnover of GFP-Ec SsrA (Fig. 6e, filled squares) . These data demonstrate that the CTE of Msm ClpP1 plays a crucial inhibitory role in ATPase docking. Next, we monitored the docking of the cognate ATPase components ( Mtb ClpX and Mtb ClpC1) to the ClpP1 ΔCTE P2 dbl complex. Surprisingly, neither Mtb ClpX nor Mtb ClpC1 were able to mediate the turnover of either GFP-Mtb SsrA (Fig. S10b ) or FITC-casein ( Fig. S10c) respectively. Taken together, these data suggest that although the CTE obstructs ATPase docking (of Ec ClpX), removal of this feature alone is not sufficient to permit docking to the physiological relevant ATPase components ( Mtb ClpX/ Mtb ClpC1). Hence, both the presence of the CTE (that occludes the Hp of ClpP1) and the altered specificity of the Hp may have important implications for the development of novel ADEP-like antibiotics that dysregulate Clp proteases. Interestingly, several ClpP homologs contain a C-terminal extension (including human ClpP which contains a 28-residue extension). To date however, the role of these CTEs has remained unclear. In contrast to our structure of Msm ClpP1, the CTE of Hs ClpP extends away from the heptameric ring 27 . Despite this "snapshot" placing the CTE of human ClpP away from the ATPase-interface we speculate that this region (in various ClpP homologues) could play an important role in regulating ClpP function in vivo. One possibility is that the CTE (or in the case of Msm ClpP1 -the atypical Hp) may have co-evolved with an alternate Clp-protease activator to further diversify the function of the peptidase. Consistent with this idea, novel (ATP-independent) Clp protease activators have recently been identified in plants 34 . Likewise, the Mycobacterial proteasome has also been shown to function with a variety of activators (both ATP-dependent and ATP-independent) 3, [35] [36] [37] [38] . Therefore, we speculate that novel ClpP activators may exist in a variety of species which contain ClpP homologs with either an extended C-terminus or an atypical Hp.
In conclusion, our findings clearly demonstrate that, similar to Mtb ClpP1P2, the hetero-oligomeric Clp-protease complex in Msm is highly regulated. Although processing of Msm ClpP2 (and hence "activation" of the Msm ClpP1P2 complex) can proceed in the absence of an activator, the in vitro peptidase activity of Msm ClpP1P2 (for peptide and protein turnover) requires either a cognate ATPase component or a chemical activator (i.e. z-LL). Significantly, both cognate ATPase components dock to only one face of the peptidase. This asymmetry provides direct competition for ATPase-docking to the peptidase, and as a result (dependent on the abundance of each component), likely controls the delivery of specific substrates to this peptidase and hence their turnover in a tightly regulated fashion. The specific docking of both ATPase components to a single face of this machine may also provide an opportunity for further diversification of the peptidase, through docking of additional specific activators to the vacant platform on the ClpP1P2 complex.
Material and Methods
cloning. Msm clpP1 (MSMEG_4673) and clpP2 (MSMEG_4672) were amplified from M. smegmatis mc 2 155 genomic DNA (kindly provided by Prof. R. Manganelli) with specific primers (see Table S1 ), using Phusion DNA polymerase (New England Biolabs). Mtb clpP1 (Rv2460c) and clpP2 (Rv2461c) were amplified from Mtb genomic DNA (kindly provided by Ms. M. Globan, VIDRL). The amplified DNA was digested with the appropriate restriction enzymes and ligated into similarly digested plasmids. Fragments coding for unprocessed ClpP1 and ClpP2 were cloned into pET10C (and pET10N) 39 to generate either a C-or N-terminal His 10 -tagged fusion protein, while fragments coding for processed forms of ClpP1 and ClpP2 (i.e. lacking propeptide) were cloned into pHUE 40 to generate N-terminal His 6 -Ub fusion proteins. Mtb clpX cloned into pET15(b) was a kind gift from Dr. P. Genevaux (Université de Toulouse, France), and Mtb clpC1 cloned into pET30(a) was a kind gift from Dr. D. Vasudevan (Institute of Life Sciences, Bhubaneswar, India) 41 . The SsrA-tag from Mtb/Msm (AADSNQRDYALAA) was cloned into pDD173 42 by annealing specific primers (see Table S1 ) to generate a C-terminal GFP fusion (GFP-Mtb SsrA). All clones (Table S2) were verified by nucleotide sequencing.
Protein expression and purification. His 6 -tagged Ec ClpX and Ec ClpP were expressed in E. coli and purified as described previously 43 . Mtb ClpC1 and Mtb ClpX were both expressed as C-terminal His 6 -tagged fusion proteins. Mtb ClpC1-His 6 was expressed as described in 41 , while Mtb ClpX-His 6 was expressed at 16 °C in E. coli BL21 (DE3) codon+ RIL cells, following the addition of 0.5 mM IPTG. ClpP1 and ClpP2 (from either Msm or Mtb) were expressed, with either a C-terminal His 10 tag, essentially as described in 39 or alternatively with a His 6 -Ub tag (which was subsequently cleaved) as described 44 . All His 6 -tagged fusion proteins were purified using Ni-NTA-agarose beads as described previously 43 , while His 10 -tagged fusion proteins were purified essentially as described 45 . Untagged ClpP1 and ClpP2 (wild type and specific point mutants) were also generated using the Ub-fusion system 40 and purified essentially as described, using a combination of IMAC and preparative grade size exclusion chromatography (SEC).
Protein analysis by electrophoresis.
For the analysis of protein purity and protein turnover, samples were separated by 16.5% Tricine SDS-PAGE 46 . To analyse the oligomerisation/native structure of wild type and mutant ClpP1 complexes, 5 µg of purified protein was separated using 4-16% Native-PAGE Novex Bis-Tris gels (Invitrogen) essentially as described 29 and visualised by staining with Coomassie Brilliant Blue (CBB) R250. processing and peptidase assays. For processing assays, either full length Msm or Mtb ClpP1 was incubated together with full length ClpP2 (from either Msm or Mtb) at 30 °C in Buffer XP (25 mM Tris-HCl pH 7.5, 100 mM KCl, 100 mM NaCl, 20 mM MgCl 2 , 10% (v/v) glycerol, 0.025% (v/v) Triton X-100, 1 mM DTT) in the absence or presence of the activator, z-Leu-Leu-H (z-LL). Processing of ClpP (2.8 µM) was initiated, either by addition of the activator (0.5 mM), or equimolar amounts of the partner ClpP protein. The reaction was stopped (at the indicated time points), by the addition of sample buffer followed by incubation at 95 °C for 5 min. Processing of Msm ClpP was analysed by 16.5% Tris-tricine SDS-PAGE while processing of Mtb ClpP was analysed by 15% glycine SDS-PAGE. To monitor the peptidase activity of wild type and mutant ClpPs, peptide degradation assays were performed using fluorescently labelled peptides essentially as described 29 . Similarly, the turnover of GFP-Ec SsrA, GFP-Mtb SsrA or FITC-casein (by 1 µM Ec ΔNClpX, Mtb ClpX or Mtb ClpC1, respectively) was and monitored by fluorescence as described 29 . All peptide and protein degradation assays were performed in the presence of 0.5 mM z-LL (unless otherwise stated).
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www.nature.com/scientificreports www.nature.com/scientificreports/ Crystallisation of Msm ClpP1 and diffraction data collection. Purified Msm ClpP1 (in 50 mM Tris-HCl pH 8.0, 200 mM KCl) was concentrated using a Centricon-30 centrifugal concentrator (Amicon) up to 30 mg/mL.
Msm
ClpP1 crystallization experiments were performed using the vapor diffusion method. Initial high-throughput crystallization experiments were performed in house or at the CSIRO Collaborative Crystallization Centre (www. csiro.au/C3; Melbourne, Australia). For crystal optimization experiments, drops were set in 24-well plates by mixing 1 µL of protein with 1 µL of well condition and drops were equilibrated at 20 °C against a reservoir volume of 500 µl. Small hexagonal crystals were obtained in 1.8M sodium malonate pH 6.4. After two rounds of optimisation, which included changing pH, malonate concentration and protein concentration a significant improvement in the quality of the crystals was obtained. Larger hexagonal crystals (with approximate dimensions 0.3 mm × 0.2 mm × 0.1 mm) were obtained from solutions consisting of 2.1-3.4M sodium malonate pH 6.6-6.8 and a protein concentration of 5.5 mg/mL. The crystals were cryoprotected using 3M sodium malonate pH 6.5-6.9 and flash cooled in liquid nitrogen. Diffraction data was collected at 100 K at the protein crystallography beamline MX2 at the Australian synchrotron using an ADSC Quantum 315r detector. 1° oscillation images were collected for a total of 180° using a crystal-to-detector distance of 260 mm. Diffraction data were integrated and scaled with HKL2000 47 .
Structure determination and refinement. The crystal structure of Msm ClpP1 was solved by molecular replacement using BALBES 48 using the structure of M. tuberculosis ClpP as a search model (PDB: 2CBY, sequence identity 96%). The model was built using Coot 49 and refined using phenix.refine 50 and TLS (translation/libration/ screw) refinement 51 . Most of the structure could be unambiguously assigned in the electron density map except residues 1-10 at the N-terminus of each chain, and the loop region between residues 125-129, which in chains A, B, C and E were difficult to model because of poor density. The final model was validated using Molprobity 52 . Table 1 provides the statistics for the X-ray data collection and final refined model. All structural figures were generated with PyMOL. Superposition of molecules was carried out using the Secondary Structure Matching (SSM) option from the program Coot 49 .
